ANSLY:OTC-Ansell Limited (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 125.88

Change

0.00 (0.00)%

Market Cap

USD 4.22B

Volume

224.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by healthcare, life sciences, and industrial workers for a range of customers, including hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and pharmaceutical companies. The Industrial segment manufactures and markets high-performance hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOF EssilorLuxottica Société ano..

N/A

USD73.39B 748.11 29.78
ESLOY EssilorLuxottica Société ano..

+0.53 (+0.64%)

USD72.37B 726.93 29.78
HOCPF HOYA Corporation

N/A

USD42.12B 37.44 0.22
HOCPY HOYA Corporation

+0.93 (+0.81%)

USD41.96B 37.56 0.22
SDMHF Sartorius Stedim Biotech S.A

N/A

USD41.54B 87.44 61.55
CLPBF Coloplast A/S

N/A

USD35.69B 51.86 5.64
CLPBY Coloplast A/S

+0.18 (+1.08%)

USD35.02B 51.63 5.64
RSMDF ResMed Inc

N/A

USD28.34B 25.39 28.58
TRUMY Terumo Corporation

+0.41 (+1.08%)

USD28.18B 40.86 0.29
TRUMF Terumo Corporation

+0.58 (+1.52%)

USD28.11B 40.96 0.29

ETFs Containing ANSLY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.22% 59% F 54% F
Dividend Return 1.28% 71% C- 41% F
Total Return 22.50% 59% F 55% F
Trailing 12 Months  
Capital Gain 66.73% 56% F 54% F
Dividend Return 3.26% 74% C 43% F
Total Return 69.98% 56% F 54% F
Trailing 5 Years  
Capital Gain 125.03% 51% F 70% C-
Dividend Return 13.92% 100% A+ 52% F
Total Return 138.94% 55% F 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 14.33% 31% F 57% F
Dividend Return 1.96% 76% C 51% F
Total Return 16.29% 30% F 57% F
Risk Return Profile  
Volatility (Standard Deviation) 22.14% 83% B 75% C
Risk Adjusted Return 73.54% 69% D+ 93% A
Market Capitalization 4.22B 58% F 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.68 72% C- 40% F
Price/Book Ratio 2.69 73% C 40% F
Price / Cash Flow Ratio 14.52 30% F 14% F
EV/EBITDA 11.55 45% F 32% F
Management Effectiveness  
Return on Equity 13.90% 63% D 82% B-
Return on Invested Capital 10.00% 57% F 73% C
Return on Assets 6.75% 74% C 90% A-
Debt to Equity Ratio 33.77% 40% F 45% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.46 54% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.